HGS seeks cash for lupus treatment
02 December 2009
Christopher Spillane
Please Login to read the full article.
02 December 2009
Christopher Spillane
christopher.spillane@informausa.com
Human Genome Sciences (HGS) is offering up to 12.5 million shares of its common stock to fund manufacturing and development of Benlysta (belimumab), its investigational monoclonal antibody for the treatment of lupus.
The public offering would be used to increase manufacturing capacity for...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- FDA's Woodcock attributes 35 NME approvals to agency flexibility, creativity
- Zogenix plans offering of 12M shares, as it moves forward on chronic pain product
- GSK, Human Genome Sciences' lupus drug Benlysta wins European approval
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
